Ragifilimab clinical trials
Also written INCAGN01876.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2016
How each study uses ragifilimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- INCAGN01876
- 4
Studies by the year they started
4 studies that test it; most in 2017 (2)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2017 | 2 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 1
Incyte Biosciences International Sàrl (3) · European Organisation for Research and Treatment of Cancer - EORTC (1)
Often tested with
Tested in the same studies.
Afatinib (1) · Palbociclib (1) · Monalizumab (1) · Niraparib (1)
Studies
Open first, then newest update. How each study uses ragifilimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Biomarker-based Study in R/M SCCHNActive, not recruitingPhase 2European Organisation for Research and Treatment of Cancer - EORTCNCT03088059Written as INCAGN01876
- INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaWithdrawnPhase 2Incyte Biosciences International SàrlNCT05359692Written as INCAGN01876
- INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic MalignanciesTerminatedPhase 1/2Incyte Biosciences International SàrlNCT03277352Written as INCAGN01876
- A Study of INCAGN01876 in Participants With Advanced or Metastatic Solid TumorsCompletedPhase 1/2Incyte Biosciences International SàrlNCT02697591Written as INCAGN01876
Given beside what is tested · 3 — ragifilimab is usual care or a partner of the new treatment
- Phase Ib Trial of Multivalent Autophagosome Vaccine With or Without GITR Agonist, With Anti-PD-1 Immunotherapy in HNSCCActive, not recruitingPhase 1Providence Health & ServicesNCT04470024Written as INCAGN01876
- Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent GlioblastomaActive, not recruitingPhase 2University of PennsylvaniaNCT04225039Written as INCAGN01876
- Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic MalignanciesCompletedPhase 1/2Incyte Biosciences International SàrlNCT03126110Written as INCAGN01876
Codes
What other systems call ragifilimab · ClinicalTrials.gg INT017448
- UNII (FDA) O440IW9NHNRAGIFILIMABOne source FDA
- NCI Thesaurus C126643RagifilimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | O440IW9NHN | RAGIFILIMAB | One source FDA |
| NCI Thesaurus | C126643 | Ragifilimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.